



AdBio Partners promotes Emma Gasol to Partner

Paris, France & Barcelona, Spain, June 4th 2024 – AdBio Partners, a venture capital company specialized in company building and early-stage investments in Life Sciences startups, announces that Emma Gasol is promoted to Partner.

Emma Gasol, PhD, joined AdBio in October 2023, bringing over 20 years of experience in the pharma and biotech industry with significant experience in business development, transaction, and innovation management. Emma's track record includes a range of transactions from early development to commercial stage, such as in-licensing, co-development, option rights, and product acquisitions.

She started her career at Crystax Pharmaceuticals, a structure-based drug discovery biotech at the Barcelona Science Park, after her PhD at University of Barcelona. She then joined Gebro Pharma, an Austrian pharma company where she led Corporate Development activities driving portfolio growth and pipeline generation.

Prior to joining AdBio, Emma was Director of Innovation Scouting at Grifols, a global healthcare leader specializing in plasma-derived medicines, where she managed external innovation initiatives and corporate venturing, demonstrating her ability to drive deal sourcing and identify cutting-edge technologies, bridging scientific innovation and business acumen.

"Emma's promotion reflects her invaluable contribution to AdBio partners. Her extensive pharma experience and strategic approach are key and complementary to our team's skills," said **Alain Huriez**, MD, chairman & managing partner of AdBio Partners. "Her expertise enhances our strong European presence, particularly through her connections between Spain and France."

Emma Gasol commented, "I feel grateful to become a Partner at AdBio. Thank you Alain Huriez, Geoffroy de Ribains and Clément Bertholet for this recognition. It is a privilege to support bold entrepreneurs developing transformative therapies and impactful technologies and fuel the next generation of biotechs. Early-stage investment is the first step in the challenging but rewarding journey of translating academic innovations into clinical solutions."

Emma's promotion to Partner strengthens AdBio Partners' leadership team and underscores the firm's commitment to fostering innovation in the life sciences sector.

About AdBio Partners

AdBio partners is an AMF-regulated (the French Financial Market Authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects.

Its unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company's growth.

Created in 2016, AdBio partners has made 23 European investments in France, Belgium, Spain and Ireland with two funds AFB Seed Fund I* and AFB FII.

AdBio partners has developed strong relationships within the European innovation ecosystem and selected promising therapeutic innovations; as a result, it has attracted substantial international VC syndicates to its portfolio companies.



The operational team includes investment professionals with long-standing track records as entrepreneurs, combined with strong financial, scientific, medical and operational expertise.

**AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.*

www.adbio.partners

Press and analyst contacts

AdBio Partners

contact@adbio.partners
